2. Notiziario dell’Istituto Superiore di Sanità, Supplemento 23, N4, 1-2010
3. Bridge DA, et al. Clinicians fail to routinely provide reproduction counseling to HIV infected women in the United States. IAS Mexico City 2008, TUPE0911
4. Floridia M et al, Antiretroviral therapy at conception in pregnant women with HIV in Italy: wide range of variability and frequent exposure to contraindicated drugs. Antivir Ther. 2006;11(7):941-6.
5. Floridia M et al, Treatment change in pregnancy is a significant risk factor for detectable HIV-1 RNA in plasma at end of pregnancy. HIV Clin Trials. 2010 Nov-Dec;11(6):303-11.
6. Public Health Service Task Force Recommendations: Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women; 24-May 2010
7. European AIDS Clinical Society Guidelines
8. de Ruiter A, et al. British HIV Association and Children’s HIV Association guidelines for the management of HIV infection in pregnant women 2008. HIV Medicine 2008;9:452-502
9. Linee Guida Italiane sull’utilizzo dei farmaci antiretrovirali e sulla gestione diagnostico-clinica delle persone con infezione da HIV- 1
10. Kaletra - Summary of Products Characteristics
11. Robert SS et al, Lopinavir/ritonavir in pregnancy. J Acquir Immune Defic Syndr. 2009 Aug 1;51(4):456-61.
12. Kiser J, et al. Total and Unbound Lopinavir/Ritonavir Pharmacokinetics in a Concentration-guided Study of HIV-infected Women throughout Pregnancy and Post-partum. 16th CROI, Montreal 2009, #946
13. Best BM et al. Lopinavir tablet pharmacokinetics with an increased dose during pregnancy. J Acquir Immune Defic Syndr. 2010;54:381–388.
14. Cressey T et al, Pharmacokinetics and virologic response of zidovudine/lopinavir/ritonavir initiated during the third trimester of pregnancy. AIDS 2010, 24:2193–2200
15. Patterson K, et al. Pharmacokinetics of the LPV/r Tablet in HIV-infected Pregnant Women: A Longitudinal Investigation of Protein Bound and Unbound Drug Exposure with Empiric Dosage Adjustment. 18th CROI 2011, Poster # 645
16. Hermes A et al, Efficacy, Safety and Tolerability of Lopinavir/ritonavir (LPV/r) in HIV-Infected Women: Results of a Meta-Analysis of 7 Prospective, Randomized Clinical Trials (RCTs) Through 48 Weeks, presentato al 1st International Workshop on HIV & Women from Adolescence through Menopause. Washington DC, January 10 - 11, 2011
17. Lockman S et al, Antiretroviral Therapies in Women after Single-Dose Nevirapine Exposure, New England Journal of Medicine, 2010; 363;1499-1509
18. APR - Antiretroviral Pregnancy Registry International Interim Report for 1-Jan 1989 - 31 July 2010. Jan 2011
19. Barocelli S et al, Antiretroviral treatment in pregnancy: a six-year perspective on recent trends in prescription patterns, viral load suppression, and pregnancy outcomes AIDS Patient Care STDS. 2009 Jul;23(7):513-20.